ClinicalTrials.gg
CompletedNCT01396837Updated Dec 2, 2020Results posted

Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.

A Phase 2 interventional study of RedDress Wound Care System (RD1) in Neuropathic Diabetic Ulcer - Foot, sponsored by RedDress Ltd.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-02.

Sponsored by RedDress Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
250th of 322
20 · median 60
Started
2014
with 19 others
Phase 2
43 of 381
5 open now
Registered
65th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 250th largest by enrollment of the 322 interventional ones that give a count, is one of 20 that started in 2014, is one of 43 in phase 2, and was the 65th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety of the RedDress Wound Care System (RD1) in patients Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.

Read the detailed description

The investigational product, the RD1 kit, was designed to enable a care provider to create an in vitro blood clot from the patient's own blood at the point of care, in a safe and effective manner.

While many advanced modalities of treatment have been developed to heal chronic DFUs (as well as other types of chronic wounds), the vast majority have been approved for relatively non-severe wounds (e.g., Texas 1a/2a grades) and relatively healthy subjects in controlled clinical trials and typically exclude 25-75% of subjects who have several comorbidities and severe wounds. Moreover, when the results of such trials (and other trials of advanced modalities) have been subject to a systematic review, the strength of the evidence for their efficacy has been rated low or even insufficient to judge. Consequently, there is an urgent need for new technologies to be tested that can improve healing rates in all classes of chronic DFUs.

The study is a multi-center, prospective, single group safety study, consisting of 20 subjects who will complete the study (note: if any patients are lost to follow-up or withdrawn, enrollment will increase to compensate for loss of these subjects). The subjects will receive 12 weekly RD1 applications. Subject data will be kept in each site's records.

03

Conditions studied

  • Neuropathic Diabetic Ulcer - Foot

Browse trials for

Keywords

  • Diabetic Foot Ulcer
  • Diabetic Ulcer
  • Diabetic Wound
  • Chronic Ulcer
  • Chronic Wound
  • Neuropathic Diabetic Foot Ulcer
  • Neuropathic DFU
  • DFU
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥18 years of age and has type 1 or 2 diabetes
  • Texas grade 1a or 2a wound located distal to the malleolus (excluding ulcers between the toes but including those of the heel) and depth ≤ 5 mm with no exposed capsule, tendon or bone and no tunneling, undermining or sinus tracts
  • Prior to inclusion of an ulcer in the study, each wound will be reviewed for eligibility by an independent assessor using a central online review process that includes images of the ulcer.
  • For patients with potentially multiple eligible DFUs, the biggest ulcer will be chosen as the study ulcer.
  • Ulcer size between 1 cm2 and 12 cm2 (post-debridement).
  • Ulcer duration of ≥ 30 days. Time 0 for ulcer duration of ≥ 30 days is defined as the first day of screening (i.e., day -14). Subjects will need to meet all inclusion criteria, including lack of ulcer healing until day 0.
  • Study ulcer separated from other ulcers by at least 2 cm.
  • Ulcer or affected limb free of clinical signs of infection. (Subjects with wound infection at the screening visit may be treated and re-screened for participation in the study after eradication of the infection).
  • Post-debridement, ulcer free of necrotic tissue.
  • Subject has adequate vascular perfusion of the affected limb, as defined by at least one of the following: (a) Ankle-Brachial Index (ABI) ≥ 0.65 and ≤ 1.2; (b) toe pressure (plethysmography) > 50 mm Hg; (c) TcPO2 > 40 mm Hg; or (d) skin perfusion pressure (SPP) > 30 mm Hg.
  • ≤ 12.0% (diabetic patients)
  • Demonstrated adequate offloading regimen.
  • Subject must be willing to comply with the protocol including having blood drawn to create the RD1.
  • Female subjects who are capable of conceiving and all males capable of insemination must use an acceptable form of in order to participate in the study (acceptable forms of contraception include condoms for males and contraceptive pills or IUDs for women).

Exclusion criteria

Exclusion Criteria:

  • Ulcer not of neuropathic diabetic foot pathophysiology (e.g., venous, vasculitic, radiation, rheumatoid, collagen vascular disease, or arterial etiology, or pressure ulcers.).
  • Presence of underlying osteomyelitis.
  • Patient with a proven sepsis established by a blood culture in the past 2 weeks, or confirmed active infection likely to interfere with trial, such as urine tract infection.
  • History of alcohol or substance abuse, within the previous 2 months
  • Subject has participated in another clinical trial involving a device or a systemically administered study drug or treatment within 30 days of randomization visit.
  • Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive a medication or treatment which, in the opinion of the Investigator, is known to interfere with, or affect the rate and quality of, wound healing (e.g., systemic , therapy, disease therapy, cytostatic therapy within the past 12 months, dialysis, radiation therapy to the foot, vascular surgery, angioplasty or thrombolysis).
  • Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes (e.g., Regranex®, Dermagraft®, Apligraf®, GraftJacket®, OASIS®, Primatrix®, Matristem®, etc.) within 30 days of randomization or is scheduled to receive during the study.
  • Subject has been treated with hyperbaric oxygen within 5 days of screening or is scheduled to receive during the study.
  • Wound on a patient who has a of less than 12 months.
  • Subjects who are cognitively impaired and have a healthcare proxy or those who are cognitively impaired and clearly do not understand the contents of the form.
  • Cannot withdraw blood in the required amount (up to 10 mL per week) technically.
  • Known coagulation problems, abnormal level or if heparin is given intravenously. Patients who are taking coumadin, aspirin, or Plavix (clopidogrel) will not be excluded.
  • anemia (\< 10 g/dL).
  • Subject has a history of or any of the following intercurrent illnesses or conditions that would compromise the safety of the subject, or the normal wound healing process:

    • End stage renal disease
    • Immunosuppression.
    • Severe malnutrition
    • Liver disease
    • Scleroderma
    • Acquired immune deficiency disease (AIDS) or positive
    • Connective tissue disorder
    • Exacerbation of sickle cell anemia
  • If ulcer area decreases by ≥ 30% during the initial 2-week screening (± 2 days) and standard of care phase, or if the ulcer area increases ≥ 30%, subject will be excluded.
  • Women who are pregnant or currently breast feeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    RedDress Wound Care System (RD1)

    RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit

    Device: RedDress Wound Care System (RD1)

Interventions

  • DeviceRedDress Wound Care System (RD1)

    Weekly application. A blood based wound care treatment

    Also known as: RedDress Wound Care System, RD1

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    Adverse event rate will be calculated including serious adverse events (SAEs), adverse events (AEs) (including any lack of venous access events), and device-related adverse events (DRAEs) (safety population and ITT populations).

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Participants Experience Complications Due to Lack of Venous Access

    For all patients for all 12 visits involving RD1 procedure (ITT population)

    Time frame: 12 weeks

  2. Number of Participants Achieving a Complete Wound Closure at 12 Weeks

    Defined as skin re-epithelialization without drainage or dressing requirements confirmed at 2 consecutive study visits 2 weeks apart) for DFU treated with RD1 (ITT population).

    Time frame: 12 weeks

  3. Percent of Reduction in Wound Size Over 12 Weeks (ITT Population)

    The data will also be plotted graphically week by week. Week 12 data will be used to recalculate sample size for the pivotal trial

    Time frame: 12 weeks

07

Results

Posted Nov 16, 2020

Participant flow

Participant flow — Overall Study
MilestoneRedDress Wound Care System (RD1)
Started20
Completed16
Not completed4

Outcome measures

PrimaryNumber of Participants Experiencing Adverse Events

Adverse event rate will be calculated including serious adverse events (SAEs), adverse events (AEs) (including any lack of venous access events), and device-related adverse events (DRAEs) (safety population and ITT populations).

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events
ParticipantsRedDress Wound Care System (RD1)
Number of Participants Experiencing Adverse Events20
SecondaryNumber of Participants Experience Complications Due to Lack of Venous Access

For all patients for all 12 visits involving RD1 procedure (ITT population)

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants Experience Complications Due to Lack of Venous Access
ParticipantsRedDress Wound Care System (RD1)
Number of Participants Experience Complications Due to Lack of Venous Access0
SecondaryNumber of Participants Achieving a Complete Wound Closure at 12 Weeks

Defined as skin re-epithelialization without drainage or dressing requirements confirmed at 2 consecutive study visits 2 weeks apart) for DFU treated with RD1 (ITT population).

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants Achieving a Complete Wound Closure at 12 Weeks
ParticipantsRedDress Wound Care System (RD1)
Number of Participants Achieving a Complete Wound Closure at 12 Weeks13
SecondaryPercent of Reduction in Wound Size Over 12 Weeks (ITT Population)

The data will also be plotted graphically week by week. Week 12 data will be used to recalculate sample size for the pivotal trial

Time frame:
12 weeks
Reported as:
Mean · percentage of area reduction
Percent of Reduction in Wound Size Over 12 Weeks (ITT Population)
percentage of area reductionRedDress Wound Care System (RD1)
Percent of Reduction in Wound Size Over 12 Weeks (ITT Population)67.1 (34.2 to 100)

Adverse events

Collected over Subjects were followed for 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RedDress Wound Care System (RD1)—3/20 (15%)16/20 (80%)
Most frequent serious events
Most frequent serious events
EventRedDress Wound Care System (RD1)
EmbolismBlood and lymphatic system disorders1/20
Infection,Infections and infestations1/20
Psychiatric issuePsychiatric disorders1/20
Most frequent other events
Showing 10 of 18
Most frequent other events
EventRedDress Wound Care System (RD1)
New DFUMusculoskeletal and connective tissue disorders6/20
Infection, study DFUInfections and infestations4/20
Gastrointestinal problemGastrointestinal disorders2/20
Infection, OtherInfections and infestations2/20
Sudden increase area study ulcerMusculoskeletal and connective tissue disorders2/20
Traumatic injury (not study wound)Injury, poisoning and procedural complications2/20
Infection, other woundInfections and infestations2/20
EmbolismBlood and lymphatic system disorders1/20
GoutMusculoskeletal and connective tissue disorders1/20
Pain at study ulcerInjury, poisoning and procedural complications1/20

Baseline characteristics

Age, Customized
Age, Customized(Participants)RedDress Wound Care System (RD1)
>18 year20
Sex: Female, Male
Sex: Female, Male(Participants)RedDress Wound Care System (RD1)
Female4
Male16
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RedDress Wound Care System (RD1)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White18
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Amun Research
    Miami, Florida 33185, United States
  • Barry University Clinical Research
    North Miami Beach, Florida 33169, United States
  • SerenaGroup Research Institute
    Pittsburgh, Pennsylvania 15222, United States
  • Martin Foot and Ankle
    York, Pennsylvania 17402, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Aug 2016, 27 months.

Results were first posted in Nov 2020, 4 years 3 months after primary completion.

Of 31 phase 2 interventional studies under Diabetic Foot, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2011
First posted
Jul 19, 2011
StartActual
May 2014
Primary completionActual
Aug 2016
CompletionActual
Mar 2017
Results first posted
Nov 16, 2020
Last update
Dec 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01396837
Lead sponsor
RedDress Ltd.
Responsible party
Sponsor
First posted
Jul 19, 2011
Start date
May 2014
Primary completion
Aug 2016
Completion
Mar 2017
Results posted
Nov 16, 2020
Last update
Dec 2, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion